Hananja

PREECLAMPSIA: A NEW TREATMENT USING ECLAMPSIN.

E-mail Print PDF

Hananja plc has discovered the effect of eclampsin (placental protein 13) on uterine arteries
together with its collaborators in Dr. Hamutal Meiri (Israel) and Dr. Berthold Huppertz
(Austria). The first data have been accepted for publication in Fetal Diagnosis and Therapy
under the title:

Effects of PP13 (Placental Protein 13) on the cardiovascular system in gravid and non-gravid
rodents by Sveinbjorn Gizurarson (Iceland), Berthold Huppertz (Medical University of Graz,
Austria), George Osol (University of Vermont, USA), Jon Olafur Skarphedinsson (University
of Iceland), Maurizio Mandala (University of Calabria, Italy) and Hamutal Meiri (Telemarpeh
Ltd, Israel and Israel & Galilee Faculty of Medicine in Safed, Bar Ilan University, Israel).

 
Þú ert hér: Home

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com